Drug
Bcx17725
Bcx17725: highest development phase Phase 1, developed by BioCryst Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- BioCryst Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| BCX17725 NCT06539507 | Phase 1 | Netherton Syndrome |
Latest
No recent events.
Follow Bcx17725 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.